By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Advaxis, Inc. 

The Technology Centre of New Jersey
675 U.S. Route One, South
North Brunswick  New Jersey  08902   U.S.A.
Phone: 732-545-1590 Fax: 732-545-1084


SEARCH JOBS


Industry
Biotechnology






Company News
Advaxis, Inc. Announces FDA Acceptance Of Its Investigational New Drug Application To Commence Clinical Trials Of ADXS-HPV In Combination With MedImmune (AZN)'s MEDI4736 For The Treatment Of HPV-Associated Cancers 12/15/2014 7:24:48 AM
Advaxis, Inc. Cancer Immunotherapies Featured On FOX News 12/12/2014 7:32:21 AM
Advaxis, Inc.'s Listeria-Based Lm-LLO Immunotherapy Featured in Nature Biotechnology 12/11/2014 7:38:46 AM
Advaxis, Inc. Announces FDA Acceptance Of Its Investigational New Drug Application To Commence Clinical Trials Of ADXS-PSA In Combination With Merck & Co. (MRK)'s KEYTRUDA® (Pembrolizumab) For Prostate Cancer 12/8/2014 8:01:27 AM
Advaxis, Inc. To Present At The LD Micro Conference 11/25/2014 11:16:28 AM
Advaxis, Inc. To Receive $1.7M Through New Jersey Technology Business Tax (NOL) Program 11/20/2014 2:12:51 PM
Advaxis, Inc. Submits Investigational New Drug Application For Phase 1/2 Study Of ADXS-HPV And Medimmune's MEDI4736 For The Treatment Of HPV-Associated Cervical And Head & Neck Cancer 11/12/2014 7:34:50 AM
Advaxis, Inc. Submits Investigational New Drug Application For ADXS31-142 (ADXS-PSA) For The Treatment Of Metastatic Castration Resistant Prostate Cancer 11/5/2014 8:27:17 AM
Advaxis, Inc. To Present Survival Data Of Lm-LLO Cancer Immunotherapies In Recurrent Cervical Cancer And Canine Osteosarcoma At The Society For Immunotherapy Of Cancer 29th Annual Meeting 11/4/2014 12:25:58 PM
Advaxis, Inc.'s ADXS-Cher2 Immunotherapy Demonstrates T-Cell Immune Response In Data Analysis From Canine Osteosarcoma Study 10/30/2014 10:22:33 AM
12345678910...
//-->